Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NASDAQ: CRBP · IEX Real-Time Price · USD
0.214
-0.007 (-3.30%)
At close: Aug 19, 2022 4:00 PM
0.219
+0.004 (2.007%)
After-hours: Aug 19, 2022 4:58 PM EDT

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.

It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation.

It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.

The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Logo
Country United States
Founded 2009
Industry Biotechnology
Sector Health Care
Employees 41
CEO Yuval Cohen

Contact Details

Address:
500 River Ridge Drive
Norwood, Massachusetts 02062
United States
Phone 617 963 0100
Website corbuspharma.com

Stock Details

Ticker Symbol CRBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001595097
CUSIP Number 21833P103
ISIN Number US21833P1030
Employer ID 46-4348039
SIC Code 2834

Key Executives

Name Position
Dr. Yuval Cohen Ph.D. Chief Executive Officer and Director
Sean F. Moran CPA, M.B.A., CPA, MBA Chief Financial Officer
Craig Stuart Millian M.B.A. Chief Operating Officer
Dr. Rachael Brake Ph.D. Chief Scientific Officer
Ted Jenkins Senior Director of Investor Relations and Corporate Communications
Lindsey Smith Head of Corporate Communications and Patient Advocacy
Christina Bertsch Head of Human Resources
Scott Constantine Senior Director and Head of Clinical Operations

Latest SEC Filings

Date Type Title
Aug 9, 2022 10-Q Quarterly Report
Aug 9, 2022 8-K Current Report
Jul 7, 2022 8-K Current Report
Jun 8, 2022 8-K Current Report
May 23, 2022 8-K Current Report
May 17, 2022 8-K Current Report
May 10, 2022 10-Q Quarterly Report
May 10, 2022 8-K Current Report
Apr 15, 2022 8-K Current Report
Apr 11, 2022 8-K Current Report